Management Instillo GmbH


Dr. Bernd Baumstümmler is the CEO of Instillo GmbH. He has more than 25 years of international experience in the pharmaceutical and biotech industries. He is an expert in biotechnology, process optimization, project management and business development. He has been a senior project manager for technology and biotech companies at Mediport Venture Capital Management GmbH, Berlin and held several management positions as CFO. 

 

Management NanoSaar AG


Dr. Michael Steiner is the CEO of nanoSaar AG. He has over 30 years of international experience in the chemical, consumer and health care industries. He received his Ph.D. in biochemistry at the Max-Planck-Institute in Martinsried/Munich. He was managing partner with JSB-Partners and held management consulting positions as senior partner and global healthcare practice group leader of Bain & Company and The Boston Consulting Group. 
Dr. Stefan Hagemann is the CFO of nanoSaar AG. He holds a master and a Ph.D. degree in business administration from the University of Stuttgart. During the course of a career spanning over 25 years, he has built-up his business expertise in international management consulting (The Boston Consulting Group, Munich), private equity (Alchemy Partners, Frankfurt/London), venture capital (TTM Investor GmbH, Munich) and hedge fund management (Euvestor AG, Munich). 

 

Management MJR PharmJet GmbH


Dr. Bernd Baumstümmler is the CEO of MJR PharmJet . He has more than 25 years of international experience in the pharmaceutical and biotech industries. He is an expert in biotechnology, process optimization, project management and business development. He has been a senior project manager for technology and biotech companies at Mediport Venture Capital Management GmbH, Berlin and held several management positions as CFO. 
Dr. Akif Emre Türeli is the Chief Scientific Officer of MJR PharmJet GmbH. He has more than 10 years of international R&D experience in the nanotechnology industry. He held R&D positions in various pharmaceutical companies where he had the change to walk through different stages of drug and formulation developement.  His focus is on the development of innovative formulations using the MJR nanotechnology for different industry applications.

 

Management Quasaar GmbH


Dr. Markus Limberger is CEO of Quasaar GmbH. His main focus is concentrated on the areas quality control and quality assurance of drug products and biopharmaceuticals as well as lean management, optimization of lab processes in the regulated GMP area and compliant implementations of new innovative analytical techniques into quality control. He established and managed FDA-approved QC Lab (>100 employees) and was responsible for the development of different Quality Systems.
 
Dr. Christoph Jacobs is CEO of Quasaar GmbH. From 2001 to 2005 he worked as Scientist for the Across Barriers GmbH, responsible for the physicochemical characterization of active pharmaceutical ingredients, stability studies and analytical method validation. In 2005 he moved to PHAST GmbH. He owned the position head of quality control and was responsible for the establishment and extension of the GMP areas as well as several successful inspections, including FDA. Its activities focus on quality control and development of analytical and drug release methods. Dr. Jacobs is specialist and active expert speaker for analytics and quality issues in the GMP field.
 
 

MyBiotech GmbH


Dr. Daniel Mueller is the CEO of MyBiotech GmbH. He made his PhD at the Institute of Biochemical Engineering (Prof. Dr. Elmar Heinzle) at University of Saarland. He has extensive experience in research and teaching in the field of biotechnology. He was Laboratory head with one of the leading German CROs, Pharmacelsus GmbH. There, he managed and implemented GLP- and GLP-compliant projects and was responsible for the project management with industrial and academic partners. He then changed into the field of biotech business development where he was responsible for sales / marketing activities and strategies and worked together with the leading biotech and pharma companies in the DACH region.
 
 
 
© Instillo GmbH 2014